New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

It’s just the latest landmark for Indianapolis-based Lilly, which was catapulted into the top spot as the world’s largest ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on ...

That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Bitcoin just erased all of its gains for this year — and some analysts say more turbulence could be in store for the ...

Medicare to cover obesity drugs under Trump deal for as little as $50. Kathryn Pomroy, Kiplinger’s Consumer News Service, Premium Health News Service Posted 11/18/2025 at 08:05 ...